SAN DIEGO, May 19, 2023 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced its participation in the Nasdaq Closing Bell Ceremony on May 19, 2023. The event will serve as a commemoration of National Brain Tumor Awareness Month (#GoGrayinMay), an important initiative dedicated to raising awareness and advancing research in the fight against brain cancer.
Joining forces with the Global Coalition for Adaptive Research, the influential National Brain Tumor Society, other GBM AGILE Study partners, and patients, Kintara Therapeutics aims to highlight the collective efforts and breakthroughs in cancer treatment and research. By ringing the Nasdaq Closing Bell, the event will symbolize the dedication and ongoing commitment of these organizations to combatting brain cancer on a global scale.
“We are honored to participate in the Nasdaq Closing Ceremony and ring the bell alongside the Global Coalition for Adaptive Research, the National Brain Tumor Society, and other GBM AGILE Study collaborators,” said Robert E. Hoffman, the President and CEO of Kintara Therapeutics. “This occasion serves as a testament to our commitment to improving the lives of cancer patients through innovative treatments and collaborative research efforts. Together, we strive to make significant advancements in the field of oncology.”
May is recognized as an important month for brain tumor awareness, provides a platform for individuals and organizations to come together, foster collaboration, and support groundbreaking research initiatives like the GBM AGILE Study. Kintara Therapeutics’ involvement in this event underscores its unwavering dedication to advancing cancer therapeutics and improving patient outcomes.
ABOUT KINTARA
Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for glioblastoma (GBM) and REM-001 Therapy for cutaneous metastatic breast cancer (CMBC).
VAL-083 is a ‘first-in-class’, small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara’s internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently advancing VAL-083 in the Global Coalition for Adaptive Research registrational Phase 2/3 clinical trial titled Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) Study to support the development and commercialization of VAL-083 in GBM.
Kintara also has a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 Therapy, which consists of the laser light source, the light delivery device, and the REM-001 drug product, has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. In CMBC, REM-001 has a clinical efficacy to date of 80% complete responses of CMBC evaluable lesions and an existing robust safety database of approximately 1,100 patients across multiple indications. Kintara has paused the REM-001 CMBC program to conserve cash resources.
For more information, please visit www.kintara.com or follow us on Twitter at @Kintara_Thera, Facebook and LinkedIn.
SAFE HARBOR STATEMENT
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company’s clinical trials and the GBM AGILE Study. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies; global unrest; and the continued impact of the COVID-19 pandemic. These and other factors are identified and described in more detail in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended June 30, 2022, the Company’s Quarterly Reports on Form 10-Q, and the Company’s Current Reports on Form 8-K.
CONTACTS
Investors
LifeSci Advisors
Mike Moyer, Managing Director
617.308.4306
[email protected]
Media inquiries
David Schull or Ignacio Guerrero-Ros, Ph.D.
Russo Partners
858.717.2310
646.942.5604
[email protected]
[email protected]
SOURCE Kintara Therapeutics
